Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Discovered Evolution of Genomic Sequences — from Ocean Archaea to Brain Cancer — Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer

June 19, 2012

LONDON, June 19, 2012 /PRNewswire/ — The Foundation for Research on the Nervous System, Replikins Ltd., and Bioradar UK Ltd. today announced that over 100 new synthetic Replikins vaccines for infectious diseases and cancer are now available as a result of the discovery by scientists Drs. Samuel and Elenore Bogoch of the evolution of the genomic Replikins over time — from ocean archaea to human cancer. A book on this subject will be released in September 2012.

Peak Gene Replikin Count: http://www.ereleases.com/pic/2012-Peak-Gene-Replikin-Count.jpg

Drs. Bogoch have determined that the highest peak gene Replikin Counts are six-fold greater in brain cancer than the Counts in ocean archaea and viruses. The ability to specify certain increasing genomic sequences related to lethality has permitted new synthetic vaccines for organisms such as Taura Syndrome Virus, infectious salmon anemia virus, universal influenza virus strains, highly lethal drug-resistant tuberculosis, and malaria, and cancers of histological type with the highest five-year mortality rates for which vaccines have not previously been available.

Because these Replikins genomic sequences have been shown to provide 1-2 years advance notice of outbreaks, effective synthetic vaccines have been manufactured by the Companies in seven days, providing time for adequate testing, and can be delivered in freeze-dried form in literally limitless quantities.

References

Accounts of some of the work on individual products have been published 1) in eight papers in Nature Precedings 2011-2012 (http://bit.ly/MdaG8m); 2) on the companies’ website (http://www.Replikins.com), which contains over 40 news announcements from 2006-present; and 3) in patent publications from 2002-present.

Contact: Dr. S. Bogoch, 646-320-5910

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Replikins Ltd.


Source: PR Newswire